Received 06/20/2022 review began 07/23/2022 review ended 07/27/2022 published 07/31/2022

HIGHLIGHTS

  • who: Report and colleagues from the (UNIVERSITY) have published the article: Received 06/20/2022 Review began 07/23/2022 Review ended 07/27/2022 Published 07/31/2022, in the Journal: (JOURNAL) of July/31,/2022
  • what: In this case, the patient faced a therapeutical challenge for the treatment modalities because of her financial condition.

SUMMARY

    Rhabdomyosarcoma (RMS) is a mesenchymal malignancy that is correlated with pediatric malignant soft tissue sarcoma of skeletal muscle that arises from the primitive mesenchymal cell. The prevalence rate of RMS is 0.43 per . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?